NCT01124253View on ClinicalTrials.gov

Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

recombinant human endostatin

recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed

Trial Locations (1)

2000043

The Lung Cancer Center of shanghai chest Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Municipal Science and Technology Commission

OTHER_GOV

collaborator

Shanghai Chest Hospital

OTHER

collaborator

Simcere Pharmaceutical Co., Ltd

OTHER

lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT01124253 - Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC) | Biotech Hunter | Biotech Hunter